Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results.
Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000378:metabolism*; D005965:Glucuronates / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008140:Lorazepam / Q000008:administration & dosage / Q000378:metabolism*; D008297:Male; D008954:Models, Biological
D014151:Anti-Anxiety Agents; D005965:Glucuronates; D008140:Lorazepam